On April 6, Medicilon formally signed a strategic cooperation agreement with Protheragen and its affiliated companies. Leveraging a collaborative “Project + Platform” model, the two parties will integrate Protheragen’s strengths in innovative drug incubation and global project sourcing with Medicilon’s one-stop preclinical pharmaceutical R&D service platform, jointly building an efficient, compliant and internationalized drug R&D ecosystem.
Against the backdrop of global pharmaceutical industry chain restructuring and accelerated integration of innovative resources, cross-border collaboration has become central to new drug development. This partnership aligns with this trend, enabling precise alignment and complementary advantages of Sino-U.S. innovation resources.
Headquartered in New York, USA, Protheragen is a global drug R&D incubation and early-stage project empowerment platform focused on advancing first-in-class therapeutic programs. With over 10 years of cross-border experience, it has served 200+ client companies, managed 130+ high-end projects (covering 600+ assets including antibodies, small molecules, ADCs, and CGT), and continuously supports innovative drug translation and global cooperation.
As an international one-stop preclinical pharmaceutical R&D CRO, Medicilon offers full-process services spanning drug discovery, CMC and preclinical research. It holds certifications compliant with NMPA, FDA, OECD GLP standards and AAALAC, and has built R&D platforms for novel molecular drugs (antibodies, ADCs, mRNA vaccines, etc.). With mature technologies and proven cases, Medicilon has supported the overseas launch of 15+ innovative drugs.
Under the agreement, Medicilon will provide Protheragen and its affiliates with one-stop R&D services meeting international GLP standards and China-US dual-filing requirements (including drug discovery, pharmacology, preclinical safety evaluation). In return, Protheragen will assist Medicilon in overseas market expansion and international cooperation, enhancing its global service capabilities and influence to achieve two-way empowerment.
This collaboration integrates Protheragen’s global project incubation and cross-border capabilities with Medicilon’s technology platforms and compliant delivery capacity. It will support Protheragen’s global innovative projects with efficient preclinical R&D, while injecting new momentum into Medicilon’s global project sourcing and international layout, jointly building an open, win-win and sustainable global drug R&D ecosystem.
Dr. Chen Donghai, Director of Business Development at Protheragen, stated: “Protheragen identifies and nurtures first-in-class potential in early-stage projects, and Medicilon’s innovative platform and global delivery capabilities are key to translating this potential into clinical value. We will promote in-depth integration of global innovative resources to help accelerate new drug aspirations and elevate pharmaceutical innovation.”
Dr. Chen Chunlin, Founder, Chairman & CEO of Medicilon, commented: “Global new drug R&D is moving toward integration and collaboration. We are honored to partner with Protheragen, we will accelerate preclinical R&D of more innovative drugs and create sustainable value for the global pharmaceutical ecosystem.”
Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial cross-border BD consulting service to encompass segments in equity investment and project incubation.
 |
Protheragen Inc. |
 |
Quick Links |
